Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 5/20 | 0.43 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.39 |
| ▸ | CNR2 | P34972 | 7/20 | 0.37 |
| ▸ | CNR1 | P21554 | 1/20 | 0.37 |
| ▸ | APP | P05067 | 1/20 | 0.37 |
| ▸ | BACE1 | P56817 | 1/20 | 0.37 |
| ▸ | PTPN11 | Q06124 | 2/20 | 0.36 |
| ▸ | DHODH | Q02127 | 1/20 | 0.34 |
| ▸ | AHR | P35869 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5124698 | 1.00 | PGR (0.43) | PGRPDK2CNR2CNR1APP | |
| SCHEMBL5118544 | 0.90 | PDK2 (0.46) | PGRPDK2BACE1 | |
| SCHEMBL5118537 | 0.90 | PDK2 (0.46) | PGRPDK2BACE1 | |
| SCHEMBL5122784 | 0.82 | PGR (0.65) | PGRPDK2 | |
| SCHEMBL5117651 | 0.82 | PGR (0.45) | PGRCNR2CNR1PTPN11AHR | |
| SCHEMBL5122796 | 0.82 | PGR (0.65) | PGRPDK2 | |
| SCHEMBL5117659 | 0.82 | PGR (0.45) | PGRCNR2CNR1PTPN11AHR | |
| SCHEMBL5124405 | 0.81 | PGR (0.63) | PGRAPPAHR | |
| SCHEMBL5124400 | 0.81 | PGR (0.63) | PGRAPPAHR | |
| SCHEMBL5113579 | 0.81 | PGR (0.49) | PGRPDK2CNR2CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7414142-B2 | 5-aryl-indan-1-one oximes and analogs useful as progesterone receptor modulators | WYETH (US) | 2008-08-19 | — | — | US | disclosed |
| US-20070066637-A1 | 5-Aryl-indan-1-one oximes and analogs useful as progesterone receptor modulators | WYETH (US) | 2007-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070066637-A1 | 5-Aryl-indan-1-one oximes and analogs useful as progesterone receptor modulators | CYP19A1, PGR, GNRHR | PGR 2/4885PDK2 1808/4885CNR2 295/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.